Literature DB >> 17534894

CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing.

Nikolaos T Georgopoulos1, Alison Merrick, Nigel Scott, Peter J Selby, Alan Melcher, Ludwik K Trejdosiewicz.   

Abstract

CD40, a member of the tumour necrosis factor family, is expressed in a variety of epithelial cells. Although soluble CD40 agonists are growth-inhibitory, membrane-presented CD40 ligand (CD40L) induces extensive apoptosis in carcinoma cells. This study investigated whether CD40 is expressed in human colorectal carcinoma (CRC) cells and explored the functional consequences of CD40 ligation. CD40 expression in a panel of CRC lines was assessed by flow cytometry and in resected human CRCs by immunohistochemistry. CRC cells were treated in vitro with soluble CD40 agonists or cocultured with fibroblasts expressing membrane-bound CD40 ligand. Apoptosis was determined by flow cytometry using Annexin V/propidium iodide labelling and by a DNA fragmentation assay. Cytokine secretion induced by CD40 ligation was quantified by a multiplex-bead array approach. We show that CD40 is expressed in a proportion of established CRC lines in culture and that receptor expression is functional. Activation of CD40 by membrane-presented CD40L, but not soluble agonists, causes high levels of death in CD40-positive CRC cells and induces secretion of proinflammatory cytokines. In agreement with our in vitro observations, immunohistochemical studies demonstrated that CD40 is highly expressed in a proportion of colorectal cancer specimens. The high level of susceptibility of CRC cells to CD40-killing combined with the ability of CD40 to induce concomitant secretion of proinflammatory cytokines suggest that CD40 ligation may represent a novel mechanism for elimination of CRC cells and render CD40 a promising therapeutic target for the eradication of colorectal tumours. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534894     DOI: 10.1002/ijc.22846

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

2.  An in vitro Co-culture System for the Activation of CD40 by Membrane-presented CD40 Ligand versus Soluble Agonist.

Authors:  Khalidah Ibraheem; Christopher J Dunnill; Myria Ioannou; Albashir Mohamed; Balid Albarbar; Nikolaos T Georgopoulos
Journal:  Bio Protoc       Date:  2018-07-05

3.  High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer.

Authors:  Zoltan Herold; Magdolna Herold; Gyorgy Herczeg; Agnes Fodor; Attila Marcell Szasz; Magdolna Dank; Aniko Somogyi
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

4.  CD40 activation in human pancreatic islets and ductal cells.

Authors:  D Klein; F Timoneri; H Ichii; C Ricordi; R L Pastori
Journal:  Diabetologia       Date:  2008-07-26       Impact factor: 10.122

5.  Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice.

Authors:  Yong-fang Jiang; Jing Ma; Yan He; Yong-hong Zhang; Yun Xu; Guo-zhong Gong
Journal:  J Zhejiang Univ Sci B       Date:  2009-01       Impact factor: 3.066

6.  Differential regulation of growth-promoting signalling pathways by E-cadherin.

Authors:  Nikolaos T Georgopoulos; Lisa A Kirkwood; Dawn C Walker; Jennifer Southgate
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

7.  Multifunctional CD40L: pro- and anti-neoplastic activity.

Authors:  Aleksandra Korniluk; Halina Kemona; Violetta Dymicka-Piekarska
Journal:  Tumour Biol       Date:  2014-08-13

8.  A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis.

Authors:  C J Dunnill; K Ibraheem; A Mohamed; J Southgate; N T Georgopoulos
Journal:  Oncogene       Date:  2016-11-21       Impact factor: 9.867

9.  Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.

Authors:  Ihab Abd-Elrahman; Taher Nassar; Noha Khairi; Riki Perlman; Simon Benita; Dina Ben Yehuda
Journal:  Oncogene       Date:  2020-10-30       Impact factor: 9.867

Review 10.  Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.

Authors:  Julie Jacobs; Evelien Smits; Filip Lardon; Patrick Pauwels; Vanessa Deschoolmeester
Journal:  J Immunol Res       Date:  2015-10-29       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.